{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:00:08Z","timestamp":1792083608594,"version":"4.4.0"},"reference-count":38,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To seek predictors of therapeutic response to the interleukin (IL)-1 inhibitor anakinra in children with systemic-onset juvenile idiopathic arthritis (sJIA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>The clinical charts of all patients with sJIA who were newly treated with anakinra at our center between 2004 and 2017 were reviewed retrospectively. Predictors included baseline demographic, clinical, and laboratory variables as well as previous or concomitant therapies. The effectiveness of anakinra was assessed at 1 year after treatment start. Complete clinical response (CCR) was defined as absence of fever, physician\u2019s global assessment \u2264 1, count of active joints \u2264 1, negative C-reactive protein, and \u2265 75% reduction of corticosteroid dose. According to the intention-to-treat principle, patients who had anakinra discontinued before 1 year for any reasons other than disease remission were classified as nonresponders. Statistics included univariate and multivariable analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Of the 62 patients included in the study, 24 (39%) met the criteria for CCR at 1 year, whereas 38 (61%) did not. On multivariable analysis, independent correlations with achievement of CCR were identified for shorter disease duration, lower active joint count, higher ferritin level, and greater activity of systemic manifestations. The area under the curve of the model was 0.83.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Our findings help to delineate the clinical profile of patients with sJIA who are more likely to benefit from IL-1 blockade. They also underscore the need for studies aimed at examining the therapeutic role of early IL-1 inhibition and to identify biomarkers predicting response to either IL-1 or IL-6 antagonists.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.180331","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T12:24:16Z","timestamp":1547555056000},"page":"416-421","source":"Crossref","is-referenced-by-count":43,"title":["Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"46","author":[{"given":"Benedetta","family":"Saccomanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9878-1292","authenticated-orcid":false,"given":"Jessica","family":"Tibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-8422","authenticated-orcid":false,"given":"Francesca","family":"Minoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1601-9518","authenticated-orcid":false,"given":"Francesca","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-8720","authenticated-orcid":false,"given":"Angela","family":"Pistorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5465-3117","authenticated-orcid":false,"given":"Andressa","family":"Guariento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-7846","authenticated-orcid":false,"given":"Roberta","family":"Caorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-7614","authenticated-orcid":false,"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-1916","authenticated-orcid":false,"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9658-0385","authenticated-orcid":false,"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"key":"2019040109152888000_46.4.416.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"2019040109152888000_46.4.416.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160173"},{"key":"2019040109152888000_46.4.416.3","doi-asserted-by":"crossref","unstructured":"De Benedetti F Schneider R . Systemic juvenile idiopathic arthritis. In: Cassidy JT Petty RE Laxer RM Lindsley CB , editors. Textbook of pediatric rheumatology, 6th ed. Philadelphia: Elsevier Saunders; 2011:236\u201348.","DOI":"10.1016\/B978-1-4160-6581-4.10014-7"},{"key":"2019040109152888000_46.4.416.4","doi-asserted-by":"crossref","unstructured":"Ravelli A . Handbook of juvenile idiopathic arthritis. Urdorf, Switzerland: Adis; 2015:1\u2013124.","DOI":"10.1007\/978-3-319-08102-1_1"},{"key":"2019040109152888000_46.4.416.5","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2019040109152888000_46.4.416.6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 inhibition in systemic juvenile idiopathic arthritis","volume":"7","author":"Giancane","year":"2016","journal-title":"Front Pharmacol"},{"key":"2019040109152888000_46.4.416.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.10885"},{"key":"2019040109152888000_46.4.416.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014886"},{"key":"2019040109152888000_46.4.416.9","first-page":"935","article-title":"Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis","volume":"32","author":"Kimura","year":"2005","journal-title":"J Rheumatol"},{"key":"2019040109152888000_46.4.416.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120842"},{"key":"2019040109152888000_46.4.416.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"2019040109152888000_46.4.416.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.24777"},{"key":"2019040109152888000_46.4.416.13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050473"},{"key":"2019040109152888000_46.4.416.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254"},{"key":"2019040109152888000_46.4.416.15","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.532785"},{"key":"2019040109152888000_46.4.416.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.23437"},{"key":"2019040109152888000_46.4.416.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076034"},{"key":"2019040109152888000_46.4.416.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1212640"},{"key":"2019040109152888000_46.4.416.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099"},{"key":"2019040109152888000_46.4.416.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141567"},{"key":"2019040109152888000_46.4.416.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.30128"},{"key":"2019040109152888000_46.4.416.22","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2019040109152888000_46.4.416.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.3.197"},{"key":"2019040109152888000_46.4.416.24","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"2019040109152888000_46.4.416.25","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20497"},{"key":"2019040109152888000_46.4.416.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.34373"},{"key":"2019040109152888000_46.4.416.27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22393"},{"key":"2019040109152888000_46.4.416.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.23916"},{"key":"2019040109152888000_46.4.416.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213030"},{"key":"2019040109152888000_46.4.416.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170703"},{"key":"2019040109152888000_46.4.416.31","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/acr.21973","article-title":"It is worth including assessment of disease activity state in juvenile arthritis clinical trials","volume":"65","author":"Consolaro","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2019040109152888000_46.4.416.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.38042"},{"key":"2019040109152888000_46.4.416.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.11.025"},{"key":"2019040109152888000_46.4.416.34","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2012.3"},{"key":"2019040109152888000_46.4.416.35","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2019040109152888000_46.4.416.36","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2019040109152888000_46.4.416.37","first-page":"79","article-title":"Macrophage activation syndrome during anti-IL-1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis","volume":"3","author":"Lurati","year":"2005","journal-title":"Pediatr Rheumatol Online J"},{"key":"2019040109152888000_46.4.416.38","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.180331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T07:30:54Z","timestamp":1573716654000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.180331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,1]]},"published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.3899\/jrheum.180331"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.180331","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,15]]}}}